A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429
This study is recruiting at 45 US sites in 19 states, according to its ClinicalTrials.gov record last updated .
Summary
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic HER2-positive Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Jazz Pharmaceuticals
- Last updated on ClinicalTrials.gov
- February 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- Mayo Clinic Scottsdale - PPDS · Phoenix, AZ
- University of Arizona Cancer Center · Tucson, AZ
California · 4
- The Oncology Institute Of Hope And Innovation · Cerritos, CA
- Los Angeles Hematology Oncology Medical Group Glendale · Glendale, CA
- USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS · Los Angeles, CA
- UCSF at Mission Bay MB · San Francisco, CA
Colorado · 2
- University of Colorado-Cancer Center-PPDS · Aurora, CO
- Rocky Mountain Cancer Centers · Denver, CO
District of Columbia · 2
- Medstar Georgetown University Hospital · Washington D.C., DC
- Washington Cancer Center · Washington D.C., DC
Florida · 4
- Florida Cancer Specialists Research South · Fort Myers, FL
- Mayo Clinic Jacksonville - PPDS · Jacksonville, FL
- Florida Cancer Specialists Research North · St. Petersburg, FL
- Florida Cancer Specialists Research East · West Palm Beach, FL
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Minnesota · 2
- Minnesota Oncology Hematology · Coon Rapids, MN
- Mayo Clinic - PPDS · Rochester, MN
Missouri · 1
- Saint Luke's Cancer Institute · Kansas City, MO
New Jersey · 2
- Hackensack Meridian Health · Hackensack, NJ
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
New York · 4
- Memorial Sloan Kettering · Long Island City, NY
- Columbia University Medical Center 161 Fort Washington · New York, NY
- Perlmutter Cancer Center 160 E 34th St · New York, NY
- The Mount Sinai Hospital · New York, NY
North Carolina · 3
- Messino Cancer Center · Asheville, NC
- Duke Cancer Institute · Durham, NC
- UNC Central Investigational Drug Services · Morrisville, NC
Ohio · 1
- Oncology Hematology Care (OHC) · Cincinnati, OH
Pennsylvania · 2
- Abramson Cancer Center of The University of Pennsylvania · Philadelphia, PA
- Fox Chase Cancer Center · Philadelphia, PA
Rhode Island · 1
- Rhode Island Hospital · Providence, RI
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Texas · 8
- Texas Oncology - Fort Worth · Fort Worth, TX
- U.T. MD Anderson Cancer Center, Investigational Pharmacy Services · Houston, TX
- Maryland Oncology Hematology Healing Way - USOR · Irving, TX
- Medical Oncology Hematology Consultants · Irving, TX
- Nexus Health · Irving, TX
- Sansum Clinic 540 W - USOR · Irving, TX
- Texas Oncology Gulf Coast · Irving, TX
- Texas Oncology West · Irving, TX
Virginia · 3
- Virginia Cancer Specialists · Fairfax, VA
- Virginia Oncology Associates, Sentara Health · Norfolk, VA
- Blue Ridge Cancer Care · Roanoke, VA
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Wisconsin · 1
- Froedtert and The Medical College of Wisconsin · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.